3 203

Cited 37 times in

Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08

DC FieldValueLanguage
dc.contributor.author백순명-
dc.date.accessioned2014-12-18T09:53:52Z-
dc.date.available2014-12-18T09:53:52Z-
dc.date.issued2013-
dc.identifier.issn0027-8874-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/89034-
dc.description.abstractNational Surgical Adjuvant Breast and Bowel Project protocol C-08 tested the worth of adding 1 year of bevacizumab to oxaliplatin-based standard adjuvant chemotherapy regimen in the treatment of stage II/III colon cancer. Although the overall result was negative, the possibility that a molecularly defined subset could benefit from bevacizumab cannot be ruled out. We performed post hoc Cox regression analyses to test for marker-by-treatment interactions for standard pathological features and survival analyses using the Kaplan-Meier method. All statistical tests were two-sided and considered statistically significant at the .05 level. Patients diagnosed with mismatch repair defective (dMMR) tumors derived statistically significant survival benefit from the addition of bevacizumab (hazard ratio [HR] = 0.52; 95% confidence interval [CI] = 0.29 to 0.94; P = .02) in contrast with no benefit in patients diagnosed with mismatch repair proficient tumors (HR = 1.03; 95% CI = 0.84 to 1.27; p = .78; P(interaction)= .04). Although a post hoc finding, this data suggests that a molecularly defined subset of colon cancer patients may derive clinical benefit from antiangiogenesis agents and underscores the need for independent validation in other clinical trials.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAngiogenesis Inhibitors/administration & dosage-
dc.subject.MESHAngiogenesis Inhibitors/therapeutic use*-
dc.subject.MESHAntibodies, Monoclonal, Humanized/administration & dosage-
dc.subject.MESHAntibodies, Monoclonal, Humanized/therapeutic use*-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHBevacizumab-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHColonic Neoplasms/drug therapy*-
dc.subject.MESHColonic Neoplasms/genetics*-
dc.subject.MESHColonic Neoplasms/pathology-
dc.subject.MESHDNA Mismatch Repair/drug effects*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHImmunohistochemistry-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOdds Ratio-
dc.subject.MESHOrganoplatinum Compounds/administration & dosage-
dc.subject.MESHProto-Oncogene Proteins B-raf/genetics-
dc.subject.MESHTreatment Failure-
dc.subject.MESHVascular Endothelial Growth Factor A/antagonists & inhibitors-
dc.titleDefective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Life Science (의생명과학부)-
dc.contributor.googleauthorKay Pogue-Geile-
dc.contributor.googleauthorGreg Yothers-
dc.contributor.googleauthorYusuke Taniyama-
dc.contributor.googleauthorNoriko Tanaka-
dc.contributor.googleauthorPatrick Gavin-
dc.contributor.googleauthorLinda Colangelo-
dc.contributor.googleauthorNicole Blackmon-
dc.contributor.googleauthorCorey Lipchik-
dc.contributor.googleauthorSeong Rim Kim-
dc.contributor.googleauthorSaima Sharif-
dc.contributor.googleauthorCarmen Allegra-
dc.contributor.googleauthorNicholas Petrelli-
dc.contributor.googleauthorMichael J. O’Connell-
dc.contributor.googleauthorNorman Wolmark-
dc.contributor.googleauthorSoonmyung Paik-
dc.identifier.doi10.1093/jnci/djt140-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01823-
dc.relation.journalcodeJ01896-
dc.identifier.eissn1460-2105-
dc.identifier.pmid23821759-
dc.identifier.urlhttp://jnci.oxfordjournals.org/content/105/13/989.long-
dc.subject.keywordAdult-
dc.subject.keywordAged-
dc.subject.keywordAngiogenesis Inhibitors/administration & dosage-
dc.subject.keywordAngiogenesis Inhibitors/therapeutic use*-
dc.subject.keywordAntibodies, Monoclonal, Humanized/administration & dosage-
dc.subject.keywordAntibodies, Monoclonal, Humanized/therapeutic use*-
dc.subject.keywordAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.keywordBevacizumab-
dc.subject.keywordChemotherapy, Adjuvant-
dc.subject.keywordColonic Neoplasms/drug therapy*-
dc.subject.keywordColonic Neoplasms/genetics*-
dc.subject.keywordColonic Neoplasms/pathology-
dc.subject.keywordDNA Mismatch Repair/drug effects*-
dc.subject.keywordFemale-
dc.subject.keywordHumans-
dc.subject.keywordImmunohistochemistry-
dc.subject.keywordKaplan-Meier Estimate-
dc.subject.keywordMale-
dc.subject.keywordMiddle Aged-
dc.subject.keywordNeoplasm Staging-
dc.subject.keywordOdds Ratio-
dc.subject.keywordOrganoplatinum Compounds/administration & dosage-
dc.subject.keywordProto-Oncogene Proteins B-raf/genetics-
dc.subject.keywordTreatment Failure-
dc.subject.keywordVascular Endothelial Growth Factor A/antagonists & inhibitors-
dc.contributor.alternativeNamePaik, Soon Myung-
dc.contributor.affiliatedAuthorPaik, Soon Myung-
dc.rights.accessRightsnot free-
dc.citation.volume105-
dc.citation.number13-
dc.citation.startPage989-
dc.citation.endPage992-
dc.identifier.bibliographicCitationJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol.105(13) : 989-992, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.